Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irofulven (Primary) ; Spironolactone
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Brain cancer; Brain metastases; Gastrointestinal stromal tumours; Glioblastoma; Glioma; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Thymic epithelial tumour; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Lantern Pharma

Most Recent Events

  • 04 May 2026 Protocol has been amended to include one new arm Experimental: Supplement D and to remove one arm Experimental: Supplement B.
  • 04 May 2026 Planned End Date changed from 9 Sep 2025 to 28 Jul 2026.
  • 04 May 2026 Planned primary completion date changed from 28 Feb 2025 to 28 Jul 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top